Boehringer Ingelheim’s immuno-oncology pipeline has taken a significant step as the company is adding an innovative preclinical program with the acquisition of Nerio Therapeutics for a total of up to $1.3 billion. Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio to achieve its aim of improving cancer patient outcomes.
Nerio’s small molecules inhibit the protein tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2), which act as immune checkpoints. Through this mechanism, PTPN1/2 inhibition can activate the immune system to fight cancer cells.
Immune checkpoint blockade with current checkpoint inhibitors has transformed the cancer treatment landscape. However, while this approach works for some patients, it does not provide a therapeutic benefit for all. Boehringer Ingelheim is committed to changing this paradigm and extending the benefits of immuno-oncology to more cancer patients with a comprehensive portfolio of therapies based on immune checkpoint blockade to boost the immune system and direct it toward cancer cells. Nerio’s small molecule inhibitors will be an important addition to Boehringer Ingelheim’s portfolio with the potential to act as a single agent therapy and, importantly, in combination with many cancer therapies already being developed in-house.
“Securing the rights to Nerio Therapeutics’ novel checkpoint inhibitors creates a broad panel of exciting new cancer treatment combination opportunities. This brings us a major step closer to our vision of transforming the lives of people living with cancer,” said Paola Casarosa, Member of the Board of Managing Directors at Boehringer Ingelheim with responsibility for the Innovation Unit.
Sanford Madigan, partner at Avalon BioVentures, L.P. and co-founder and CEO of Nerio Therapeutics, said: “We believe Nerio’s small molecule PTPN1/N2 inhibitors have superior drug-like properties and provide a first-in-class opportunity. We are excited to expand Boehringer Ingelheim’s pipeline and commend their commitment to unlock the full potential of our compounds and their mechanistically unique approach to fighting cancer.”
